Vitamin D and the Selected Diseases of the Nervous System
DOI:
https://doi.org/10.15225/PNN.2015.4.2.6Keywords
vitamin D, diseases of the nervous systemAbstract
Interest in the role of vitamin D in the human body has greatly increased in the last decade. Many scientific studies
provide the evidence of vitamin D deficiency, which is considered to be one of the most serious health problems in
children, young people as well as those middle-aged and older people. The effects of vitamin D deficiency in the
prenatally period can affect the health condition at later age, and can be related to diseases of chronic and progressive nature. Nowadays, vitamin D is seen rather as a hormone and is said to have pleiotropic effect. Apart from its
classical effect on calcium and phosphate metabolism, vitamin D is also applied in the prophylaxis and treatment
of the cardiovascular system and metabolic diseases, cancer or autoimmune diseases. Taking into account scientific
reports on certain diseases of the nervous system, there is an indication regarding a relationship between their occurrence and the deficit of vitamin D. Therefore, this vitamin can be seen as a potential “candidate” to support the
prevention as well as treatment of these diseases. It should be emphasized however, that not everything in this
matter is absolutely certain and clear; further studies are still required in this area. (JNNN 2015;4(2):85–90)
References
Stumpf W.E., Sar M., Reid F.A. et al. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science. 1979;206 (4423):1188–1190.
Brumbaugh P.F., Haussler D.H. Nuclear and cytoplasmic receptors for 1,25-dihydroxycholecalciferol in intestinal mucosa. Biochemical Biophysical Research Communications. 1973;51(1):74–80.
Brumbaugh P.F., Haussler D.H., Bressler R. et al. Radioreceptor assay for 1 alpha, 25-dihydroxyvitamin D3. Science. 1974;183:1089–1091.
Garcion E., Wion-Barbot N., Montero-Menei CN. New clues about vitamin D functions in the nervous system. Trends Endocrinology & Metabolism. 2002;13(3):100–105.
Hyppönen E., Läärä E., Reunanen A. et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001;358(3):1500–1503.
Dong J.Y., Zhang W., Chen J.J. et al. Vitamin D intake and risk of type 1 diabetes: a meta-analysis of observational studies. Nutrients. 2013;5(9):3551–3562. doi:10.3390/nu5093551.
Song Y., Wang L., Pittas A.G. Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care. 2013;36(5):1422–1428.doi:10.2337/dc12-0962.
Talaei A., Mohamadi M., Agdi Z. The effect of vitamin D on insulin resistance in patients with type 2 diabetes. Diabetology & Metabolic Syndrome. 2013;5:8. doi: 10.1186/1758-5996-5-8.
Hong Q., Xu J., Xu S. et al. Associations between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritis. Rheumatology. 2014;53(11):1994–2001. doi: 10.1093/rheumatology/keu173.
Kostoglou-Athanassiou J., Athanassiou A., Lyraki A. et al. Vitamin D and rheumatoid arthritis. Therapeutic Advances Endocrinology & Metabolism. 2012;3(6):181–187. doi: 10.1177/2042018812471070.
Ma Y., Zhang P., Wang F. et al. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. Journal Clinical Oncology. 2011;29(28):3775–3782. doi: 10.1200/JCO.2011.35.7566.
Gandini S., Boniol M., Haukka J. et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. International Journal Cancer. 2011;128(6):1414–1424. doi: 10.1002/ijc.
Lappe J.M., Gustafson-Travers D., Davies M.K. et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. American Journal Clinical Nutrition. 2007;80:1586–1591.
Grace P., Brehm J.M., Alcorn J.F. Vitamin D and asthma. American Journal Respiratory and Critical Care Medicine. 2012;185:124–132.
Devereux G., Wilson A., McNeill G. et al. A case-control study of vitamin D status and asthma in adults. Allergy. 2010;65:666–667.
Judd S.E., Nanes M.S., Ziegler T.R. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. American Journal Clinical Nutrition. 2008;87(1):136–141.
Pfeifer M., Begerow B., Minne H.W. et al. Effects of a short-term vitamin D(3) and calcium supplementation on the blood pressure and parathyroid hormone levels in elderly women. Journal Clinical Endocrinology & Metabolism. 2001;86:1633–1637.
Beveridge L.A., Struthers A.D., Khan F. et al. Effect of vitamin D supplementation on blood pressure: a systematic review and meta-analysis incorporating individual patient data. JAMA Internal Medicine. 2015;16 Mar. doi: 10.1001/jamainternmed.2015.0237.
Siuda J., Boczarska-Jedynak M., Krzystanek E. i wsp. Rozpowszechnienie wybranych chorób neurologicznych w wieku podeszłym. W: Mossakowska M., Więcek A., Błędowski P. (Red.), Aspekty medyczne, psychologiczne, socjologiczne i ekonomiczne starzenia się ludzi w Polsce. Termedia, Poznań 2012;137–154.
Newmark H.L., Newmark L. Vitamin D and Parkinson’s disease — a hypothesis. Movement Disorders. 2007;22(4):461–468.
Evatt M.L., DeLong M.R., Khazi N. et al. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Archives Neurology. 2008;65(10):1348–1352. doi: 10.1001/archneur.65.10.1348.
Knekt P., Kilkkinen A., Rissanen H. et al. Serum vitamin D and the risk of Parkinson Disease. Archives Neurology. 2010;67(7):808–811.
Suzuki M., Yoshioka M., Hashimoto M. et al. 25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson’s disease. Movement Disorders. 2012;27:264–271.
Suzuki M., Yoshioka M., Hashimoto M. et al. Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. American Journal Clinical Nutr. 2013;97:1004–1013.
Clifford R.J., Albert M.S., Knopman D.S. et al. Introduction to the recommendations from the National Institute on Ageing-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dementia. 2011;7:257–262.
Barcikowska M. Choroba Alzheimera. W: Rekomendacje Interdyscyplinarnej Grupy Ekspertów Rozpoznawania i Leczenia Otępień (IGERO). Rozpoznawanie i leczenie otępień. Czelej, Lublin 2006;34–51.
Annweiler C., Schott AM., Allali G. et al. Association of vitamin D deficiency with cognitive impairment in older women. Neurology. 2010;74:27–32.
Buell J.S., Dawson-Hughes B., Scott T.M. et al. 25-Hydroxyvitamin D, dementia and cerebrovascular pathology in elders receiving home services. Neurology. 2010;74:18–26.
Littlejohns T.J., Henley W.E., Lang A. et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014;83(10):920–928.
Llewelyn D.J., Lang I.A., Langa K.M. et al. Vitamin D and risk of cognitive decline in elderly persons. Archives Internal Medicine. 2010;170(13):1135–1141.
Breitling P.R., Perna L., Müller H. et al. Vitamin D and cognitive functioning in the elderly population in Germany. Experimental Gerontology. 2012;47(1):122–127.
Chei C.L., Roman P., Yin Z.X. et al. Vitamin D levels and cognition in elderly adults in China. Journal American Geriatrics Society. 2014;62(11):2125–2129.
Polman Ch.H., Thompson A.J., Murray T.J., Bowling A.C., Noseworthy J.H. Stwardnienie rozsiane. PZWL, Warszawa 2011.
Anuszewska E. Nowe spojrzenie na witaminę D. Gazeta Farmaceutyczna. 2011;2:32–35.
Kotb M.A., Sayed S.S. Relation between serum vitamin D levels and activity of multiple sclerosis. Egyptian Journal Neurology, Psychiatry & Neurosurgery. 2014;51(1):123–129.
Kragt J.J., van Amerongen B.M., Killestein J. et al. Hogher levels of 25-dihydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Multilpe Sclerosis. 2009;15:9–15.
Munger K.L., Lynn I.L., Hollis B. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832–2838.
Magzhanov R.V., Sharafutdinova L.R., Bakhtiyarova K.Z. Seasonal pattern to multiple sclerosis in newborns in Bashkortostan. Saratov Journal Medical Scientific Research. 2013;9(4):697–699.
Willer C., Dyment D.A., Sandovnick A.D. et al. Timing of birth and risk of multiple sclerosis: population based study. British Medical Journal. 2005;330(7483):120. doi:10.1136/bmi.38301.686030.63.
Dudani S.J., Kalhan S., Sharma S.P. Vitamin D and multiple sclerosis: Potential pathophysiolical role and clinical implications. International Journal Applied Basic Medical Research. 2011;1(2):71–74. doi:10.4103/2229-516X.91146.
Goldberg P., Fleming M.C., Pickardt E.H. Multiple sclerosis: Decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Medical Hypotheses. 1986;21:193–200.
Wingerchuk D.M., Lesaux J., Rice G.P. et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D₃) for relapsing-remitting multiple sclerosis. Journal Neurology Neurosurgery & Psychiatry. 2005;76(9):1294–1296.
Soilu-Hänninen M., Aivo J., Lindström B.M. et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. Journal Neurology Neurosurgery & Psychiatry. 2012;83:565–571. doi:10.1136/jnnp-2011-301876.
Downloads
Published
How to Cite
Issue
Section
License
![Creative Commons License](http://i.creativecommons.org/l/by-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Stats
Number of views and downloads: 70
Number of citations: 0